CETP-inhibition has shown to elicit a plethora of beneficial effects on lipid metabolism, robustly decreasing the plasma concentration of canonical atherosclerosis particles such as total and small LDL, and lipoprotein (a) (Lp[a]), while increasing plasma concentrations of mature HDL, as well as pre-beta HDL and apolipoprotein-A1 (Apo-A1) [1–4]. Here, APOA1 is linked to atherosclerosis.